We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $767M
1-Year Est. Return 119.71%
This Fund
S&P 500
This Quarter Est. Return
-0.94%
1 Year Est. Return
+119.71%
3 Year Est. Return
+244.81%
5 Year Est. Return
+382.5%
10 Year Est. Return
+2,655.81%
AUM
$553M
AUM Growth
-$75.2M
Cap. Flow
-$13.2M
Cap. Flow %
-2.38%
Top 10 Hldgs %
31.54%
Holding
133
New
18
Increased
30
Reduced
36
Closed
26

Top Buys

Rank Stock Value
1
GOOG icon
Alphabet (Google) Class C
GOOG
+$7.68M
2
ANNX icon
Annexon
ANNX
+$7.65M
3
ORA icon
Ormat Technologies
ORA
+$6.1M
4
SNDX icon
Syndax Pharmaceuticals
SNDX
+$5.93M
5
SEDG icon
SolarEdge
SEDG
+$5.77M

Top Sells

Rank Stock Value
1
AAPL icon
Apple
AAPL
+$14.2M
2
TEVA icon
Teva Pharmaceutical Industries Limited
TEVA
+$10.2M
3
AMZN icon
Amazon
AMZN
+$8.8M
4
S icon
SentinelOne
S
+$6.62M
5
NICE icon
Nice
NICE
+$6.39M

Sector Composition

Rank Sector Weight
1 Healthcare 73.33%
2 Technology 15.86%
3 Communication Services 3.88%
4 Miscellaneous 3.03%
5 Consumer Discretionary 2.48%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IONS icon
76
Ionis Pharmaceuticals
IONS
$7.72B
$2.23M 0.4%
63,821
– –
VTYX
77
DELISTED
Ventyx Biosciences
VTYX
$2.22M 0.4%
1,012,749
– –
ORIC icon
78
Oric Pharmaceuticals
ORIC
$1.33B
$2.2M 0.4%
273,213
+144,817
+113% +$1.33M
CMMB
79
Chemomab Therapeutics
CMMB
$19.6M
$2.2M 0.4%
303,644
– –
XENE icon
80
Xenon Pharmaceuticals
XENE
$5.52B
$2.04M 0.37%
+52,097
New +$2.15M
PMN icon
81
ProMIS Neurosciences
PMN
$119M
$1.83M 0.33%
77,172
– –
UBER icon
82
Uber
UBER
$144B
$1.81M 0.33%
+30,000
New +$2.14M
LRMR icon
83
Larimar Therapeutics
LRMR
$403M
$1.76M 0.32%
455,604
+41,126
+10% +$271K
ZURA icon
84
Zura Bio
ZURA
$436M
$1.73M 0.31%
690,718
-48,000
-6% -$171K
SHLT
85
DELISTED
SHL Telemedicine Ltd American Depositary Shares
SHLT
$1.68M 0.3%
632,456
– –
JSPR icon
86
PUT
Jasper Therapeutics
JSPR
$21.5M
$1.66M 0.3%
+77,500
New +$1.61M
CATX icon
87
Perspective Therapeutics
CATX
$326M
$1.47M 0.27%
460,247
-129,048
-22% -$1.05M
JSPR icon
88
CALL
Jasper Therapeutics
JSPR
$21.5M
$1.31M 0.24%
61,100
– –
ATXS
89
DELISTED
Astria Therapeutics
ATXS
$1.25M 0.23%
139,800
+3,218
+2% +$34.2K
BMY icon
90
Bristol-Myers Squibb
BMY
$129B
$1.13M 0.2%
+20,000
New +$1.12M
MRSN
91
DELISTED
Mersana Therapeutics
MRSN
$987K 0.18%
+27,611
New +$1.43M
ALMS
92
Alumis Inc
ALMS
$1B
$983K 0.18%
125,000
– –
HOWL icon
93
Werewolf Therapeutics
HOWL
$46.7M
$928K 0.17%
626,810
– –
APRE icon
94
Aprea Therapeutics
APRE
$9.33M
$888K 0.16%
270,000
– –
PERI icon
95
Perion Network
PERI
$345M
$869K 0.16%
102,612
-131,997
-56% -$1.11M
OKUR
96
OnKure Therapeutics
OKUR
$119M
$751K 0.14%
+87,354
New +$1.32M
KZR
97
DELISTED
Kezar Life Sciences
KZR
$729K 0.13%
108,473
+87,956
+429% +$655K
FATE icon
98
Fate Therapeutics
FATE
$303M
$655K 0.12%
+397,177
New +$1M
ALEC icon
99
Alector
ALEC
$205M
$614K 0.11%
324,639
-295,361
-48% -$1.11M
ELEV
100
DELISTED
Elevation Oncology
ELEV
$573K 0.1%
1,018,562
-61,200
-6% -$36.1K
2 3
4
5 6

Similar funds

ISWM
Independent Solutions Wealth Management Williamsville, New York $766M AUM 31.53% 1-Year Est. Return
ACP
Albar Capital Partners London, United Kingdom $767M AUM 61.96% 1-Year Est. Return
NIM
Nexus Investment Management Toronto, Ontario, Canada $767M AUM 30.97% 1-Year Est. Return
ACM
Arvin Capital Management Austin, Texas $766M AUM 36.51% 1-Year Est. Return
CBT
Crews Bank & Trust Wauchula, Florida $766M AUM 19.5% 1-Year Est. Return
SPIA
Strategic Point Investment Advisors Providence, Rhode Island $767M AUM 17.58% 1-Year Est. Return
CNB
Camden National Bank Camden, Maine $767M AUM 14.32% 1-Year Est. Return
HI
Hendershot Investments Centreville, Virginia $766M AUM 10.81% 1-Year Est. Return

Sphera Funds Management's Q4 2024 Portfolio in Review

As of Q4 2024, Sphera Funds Management held 133 positions worth $553M, down 12% from $628M the previous quarter. Its ten largest holdings account for 32% of the portfolio.

Sphera Funds Management's Q4 2024 filing shows 18 new, 30 increased, 36 reduced and 26 closed positions. Its largest new stake was Alphabet (Google) Class C: 43,500 shares worth $8.28M. The largest sale was Apple, an estimated $14.2M.

By sector, the portfolio is most concentrated in Healthcare at 73% of assets, up from 70% a quarter earlier, followed by Technology and Communication Services.

  • Sphera Funds Management's largest Q4 2024 buy was Alphabet (Google) Class C: 43,500 shares worth $8.28M.
  • Sphera Funds Management added most to Syndax Pharmaceuticals in Q4 2024, an estimated $5.93M increase.
  • Sphera Funds Management's biggest Q4 2024 reduction was Teva Pharmaceutical Industries Limited, cutting an estimated $10.2M.
  • Sphera Funds Management fully exited Apple in Q4 2024, selling an estimated $14.2M.
  • Sphera Funds Management's ten largest holdings make up 32% of its $553M portfolio in Q4 2024.
  • Sphera Funds Management opened 18 new positions and closed 26 in Q4 2024.
  • Sphera Funds Management's portfolio value fell 12% quarter-over-quarter to $553M.

Based on Sphera Funds Management's 13F filing for Q4 2024, filed 14 Feb 2025.